Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H18ClF3N2O |
Molecular Weight | 310.743 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(=C1)C(F)(F)F
InChI
InChIKey=JSJCTEKTBOKRST-UHFFFAOYSA-N
InChI=1S/C13H18ClF3N2O/c1-12(2,3)19-6-10(20)7-4-8(13(15,16)17)11(18)9(14)5-7/h4-5,10,19-20H,6,18H2,1-3H3
DescriptionSources: http://www.scbt.com/datasheet-211757-mabuterol.htmlCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/6152155
Sources: http://www.scbt.com/datasheet-211757-mabuterol.html
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/6152155
Mabuterol is a long acting βeta 2-adrenergic agonist which stimulates adenylyl cyclase activity and the closing of calcium channels. Studies indicate that the R enantiomer of mabuterol is more potent than the S enantiomer. In addition, the half-life is longer in the R enantiomer than the S. Studies conducted on rats and dogs show that mabuterol acts as a bronchodilator. At high concentrations mabuterol can also antagonize beta1 adrenoceptors in guinea pigs
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2474351 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Use of molecularly imprinted polymers in the solid-phase extraction of clenbuterol from animal feeds and biological matrices. | 2001 Aug 5 |
|
Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems. | 2002 Aug |
|
Improvement in steroid screening for doping control with special emphasis on stanozolol. | 2003 Jan 24 |
|
Determination of beta-agonists in liver and retina by liquid chromatography-tandem mass spectrometry. | 2005 Jan-Feb |
|
Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry. | 2005 Jan-Feb |
|
Enantioselective pharmacokinetics of mabuterol in rats studied using sequential achiral and chiral HPLC. | 2005 Nov |
|
Application of an enzyme-linked immunosorbent assay for the detection of clenbuterol residues in swine urine and feeds. | 2007 Feb |
|
Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. | 2007 Nov |
|
Validation of radioimmunoassay screening methods for beta-agonists in bovine liver according to Commission Decision 2002/657/EC. | 2008 Dec |
|
Simultaneous enantioseparation of four beta2-agonists by capillary electrophoresis with cyclodextrin additives. Study of the enantioselective mechanism. | 2008 Dec |
|
[Multi-residue analysis of 10 beta2-agonists in animal tissues using gas chromatography-mass spectrometry]. | 2008 Jan |
|
How to decrease ion suppression in a multiresidue determination of beta-agonists in animal liver and urine by liquid chromatography-mass spectrometry with ion-trap detector. | 2009 Apr 1 |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
[Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry]. | 2010 Aug |
|
Development and validation of a liquid chromatography tandem mass spectrometry method for the analysis of beta-agonists in animal feed and drinking water. | 2010 Sep 24 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3995
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
C044573
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
SUB08631MIG
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
100000081736
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
5089
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
m6973
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL86749
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
MABUTEROL
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
1623
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
R4K19W6S7Q
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
C81647
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
56341-08-3
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY | |||
|
DTXSID3048283
Created by
admin on Fri Dec 15 17:37:31 GMT 2023 , Edited by admin on Fri Dec 15 17:37:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)